source
- Weekly roundup: Experts debate China biotech work ethic and a stalled megamergerThe Endpoints News team hosted a panel of industry experts in Cambridge, Massachusetts, to examine the future of biotech in China. Participants highlighted concerns about the country’s work ethic a…
- Replimune secures FDA accelerated approval for melanoma therapy TudriqevReplimune announced that the FDA has granted accelerated approval to its melanoma therapy RP1, marketed as Tudriqev, after two earlier rejections and a third expedited review. The decision reflects…